Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Surprises From ENHANCE At ACC Mean Vytorin Hopes Hang On IMPROVE-IT

Executive Summary

CHICAGO - With the full presentation of the results of the failed ENHANCE study at the American College of Cardiology annual meeting, a ringing endorsement for statin use and the results of IMPROVE-IT four years away, the door seems almost closed on Merck/Schering-Plough's Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin)

You may also be interested in...



Merck's IMPROVE-IT: FDA Panel Review Has Implications Beyond Zetia, Vytorin

Whether FDA agrees that results from ezetimibe cardiovascular outcomes study confirm the LDL hypothesis for non-statin drugs is of keen interest to sponsors of PSCK9 inhibitors and other novel lipid-lowering agents.

IMPROVE-IT’s Mixed Blessing: How Low Does LDL Really Need To Go?

Sponsors of injectable PCSK9 biologics address questions about the implications of the IMPROVE-IT study, in which the soon-to-be-generic oral Zetia helped bring down LDL cholesterol to a very low level.

Preparing For Battle: PCSK9 Sponsors Stake Their Ground

The strong efficacy and sound safety data coming out of the Phase III programs presented at ACC have all eyes on the commercial opportunity for the PCSK9 inhibitor class. Ongoing outcomes trials and market impact of new cholesterol guidelines sparked discussion, and leading sponsors Amgen and Sanofi/Regeneron talked about the potential populations and differences in the devices and dosing of evolocumab and alirocumab.

Related Content

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel